Philips Wins FDA Nod for Rembra CT Scanning Platform

Philips has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Rembra platform of scanning systems, which includes Rembra CT, Rembra RT, and Areta RT.

The next-gen Rembra radiology CT was showcased publicly for the first time at ECR 2026. Philips said the new systems were engineered to respond to rising demand for imaging and radiation therapy planning by improving speed, efficiency, and access to high-quality imaging.

The platform extends CT’s role across diagnostic radiology and radiation therapy to allow a more coordinate approach to patient care. This ranges from rapid assessment in acute settings to precise planning of cancer treatment.

The Rembra CT features the largest-in-class (according to Philips) 85 cm bore and enables fast, high-throughput imaging in demanding clinical environments. The company said it supports up to 270 exams a day in settings including emergency departments, critical care, and interventional settings. Advanced acquisition and reconstruction capabilities support rapid, high-quality imaging at scale as well.

Rembra RT and Areta RT extend these performance advantages into radiation therapy. The systems support high-fidelity imaging for treatment planning and next-generation 4DCT imaging capabilities to more accurately target tumors while protecting healthy tissue.

“As healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions,” said Dan Xu, Business Leader of CT at Philips. “With the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.”

Last week, the company revealed it had secured FDA clearance for its Spectral CT Verida system, a next-gen, artificial intelligence (AI)-powered spectral CT system.